Endpoints News 生物医药· Elizabeth Cairns·· 3 天前AI 评分45
罗氏口服SERD抑制剂giredestrant获FDA批准用于晚期乳腺癌
Roche enters the SERD market with FDA approval in late-stage breast cancer
AI 导读
罗氏(Roche)口服选择性雌激素受体降解剂(SERD)giredestrant获美国FDA批准,用于晚期乳腺癌治疗。该药曾处于等待两个不同FDA审批决定的特殊状态。
正文
Roche’s big-hope breast cancer pill giredestrant was in an odd situation in that it was awaiting two different FDA approval decisions. Also oddly, the second …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news